| Name | Title | Contact Details |
|---|
Based in Denver, Cordant Health Solutions™ provides innovative tools for monitoring and managing behavioral health, chronic pain and criminal justice cases. Our unique programs include pharmacy, clinical laboratory and analytic tools that provide actionable information to protect prescribers, improve outcomes and contain costs. As a leader in rigorous quality and compliance standards, Cordant is committed to developing groundbreaking solutions for payers, clinicians and organizations involved in the substance use disorder, criminal justice and pain management markets. Cordant offers unique risk assessment, monitoring and management tools through its integrated network of laboratories and high-touch pharmacies specializing in the management and dispensing of controlled substances and behavioral health medications. Cordant`s testing protocols and digital case-management tools help clients become more efficient and effective in assessing and managing risk, monitoring patient adherence and improving patient outcomes.
Advantica Benefits is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
e4e is an IT-enabled Services and Business Process Outsourcing company that has deep domain and contextual expertise in the US Healthcare Business Services ecosystem, with an enviable client list of reputed companies. e4e was founded in 2000 and has over 2,500 employees globally, with offices in the U.S., India, and the Philippines. With over 150 years of cumulative senior management experience, we have the capability of delivering compelling business value to our clients, right shoring between our geographical sites and our best practices.
Sebastian International Inc is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.